Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies
Open Access

Role of MicroRNA-31 (miR-31) in Breast Carcinoma Diagnosis and Prognosis

AMAL F. GHARIB, AMANY SALAH KHALIFA, EMAD MOHAMED EED, HAMSA JAMEEL BANJER, ASHJAN ALI SHAMI, AHMAD EL ASKARY and WAEL H. ELSAWY
In Vivo May 2022, 36 (3) 1497-1502; DOI: https://doi.org/10.21873/invivo.12857
AMAL F. GHARIB
1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Kingdom of Saudi Arabia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AMANY SALAH KHALIFA
2Clinical Pathology and Pharmaceutics Department, Faculty of Pharmacy, Taif University, Taif, Kingdom of Saudi Arabia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EMAD MOHAMED EED
1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Kingdom of Saudi Arabia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dremadeed@yahoo.com
HAMSA JAMEEL BANJER
1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Kingdom of Saudi Arabia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ASHJAN ALI SHAMI
1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Kingdom of Saudi Arabia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AHMAD EL ASKARY
1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Kingdom of Saudi Arabia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WAEL H. ELSAWY
3Department of Clinical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 36 no. 3 1497-1502
DOI 
https://doi.org/10.21873/invivo.12857
PubMed 
35478111

Published By 
International Institute of Anticancer Research
Print ISSN 
0258-851X
Online ISSN 
1791-7549
History 
  • Received February 2, 2022
  • Revision received March 11, 2022
  • Accepted March 14, 2022
  • Published online April 27, 2022.

Copyright & Usage 
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

Author Information

  1. AMAL F. GHARIB1,
  2. AMANY SALAH KHALIFA2,
  3. EMAD MOHAMED EED1⇑,
  4. HAMSA JAMEEL BANJER1,
  5. ASHJAN ALI SHAMI1,
  6. AHMAD EL ASKARY1 and
  7. WAEL H. ELSAWY3
  1. 1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Kingdom of Saudi Arabia;
  2. 2Clinical Pathology and Pharmaceutics Department, Faculty of Pharmacy, Taif University, Taif, Kingdom of Saudi Arabia;
  3. 3Department of Clinical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
  1. Correspondence to: Emad Mohamed Eed, MD, Professor of Clinical Laboratory Sciences, 55 Abo Bakre Street, Taif, Kingdom of Saudi Arabia. Tel: +966 554657473, e-mail: dremadeed{at}yahoo.com
View Full Text
PreviousNext
Back to top

In this issue

In Vivo
Vol. 36, Issue 3
May-June 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Role of MicroRNA-31 (miR-31) in Breast Carcinoma Diagnosis and Prognosis
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
13 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Role of MicroRNA-31 (miR-31) in Breast Carcinoma Diagnosis and Prognosis
AMAL F. GHARIB, AMANY SALAH KHALIFA, EMAD MOHAMED EED, HAMSA JAMEEL BANJER, ASHJAN ALI SHAMI, AHMAD EL ASKARY, WAEL H. ELSAWY
In Vivo May 2022, 36 (3) 1497-1502; DOI: 10.21873/invivo.12857

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Role of MicroRNA-31 (miR-31) in Breast Carcinoma Diagnosis and Prognosis
AMAL F. GHARIB, AMANY SALAH KHALIFA, EMAD MOHAMED EED, HAMSA JAMEEL BANJER, ASHJAN ALI SHAMI, AHMAD EL ASKARY, WAEL H. ELSAWY
In Vivo May 2022, 36 (3) 1497-1502; DOI: 10.21873/invivo.12857
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Evaluation of the Relationship Between miRNA-22-3p and Gal-9 Levels in Glioblastoma
  • Metformin Inhibits the Estrogen-mediated Epithelial-Mesenchymal Transition of Ectopic Endometrial Stromal Cells in Endometriosis
  • MCC950 Ameliorates Acute Exogenous Lipoid Pneumonia Induced by Sewing Machine Oil in Rats via the NF-κB/NLRP3 Inflammasome Pathway
Show more Experimental Studies

Similar Articles

Keywords

  • miRNA-31
  • breast carcinoma
  • diagnosis
  • prognosis
In Vivo

© 2023 In Vivo

Powered by HighWire